Shots:

• The approval is based on P-III DAPA-CKD trial assessing Farxiga (qd- 10 mg) + SOC vs PBO in 4304 patients with CKD stages 2-4 and elevated urinary albumin excretion- with/out T2D
• Results: 39% reduction in relative risk of worsening of renal function or risk of CV or renal death- ARR (5.3%) @2.4yrs.- and reduction in the risk of death by 31%. The approval follows the US FDA’s PR designation granted in early 2021
• The exploratory analyses of the P-III DECLARE-TIMI 58 trial evaluating the effect of Farxiga vs PBO in 14000 patients on CV outcomes support the conclusion that Farxiga is effective in patients with less advanced CKD

  Ref: Businesswire | Image: Twitter